Immatics N.V. (NASDAQ:IMTX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $19.67.
IMTX has been the subject of a number of research analyst reports. Stifel Nicolaus started coverage on Immatics in a research report on Tuesday. They set a “buy” rating and a $15.00 target price for the company. Wall Street Zen raised Immatics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Friday, September 18th. Finally, Jefferies Financial Group set a $17.00 price objective on shares of Immatics in a research note on Tuesday, August 25th.
Get Our Latest Analysis on IMTX
Immatics Trading Down 5.7%
Immatics stock traded down $0.41 during trading on Friday, reaching $6.73. The company had a trading volume of 1,154,876 shares, compared to its average volume of 995,806. Immatics has a 52 week low of $6.65 and a 52 week high of $12.41. The firm’s 50-day simple moving average is $8.66 and its 200 day simple moving average is $9.66. The firm has a market capitalization of $919.92 million, a price-to-earnings ratio of -3.62 and a beta of 1.36.
Immatics (NASDAQ:IMTX – Get Free Report) last released its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.06). Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. The company had revenue of $10.44 million for the quarter, compared to the consensus estimate of $12.42 million. On average, analysts predict that Immatics will post -1.99 earnings per share for the current year.
Insider Transactions at Immatics
In other news, Director Perceptive Advisors Llc acquired 863,060 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average cost of $8.69 per share, with a total value of $7,499,991.40. Following the completion of the acquisition, the director owned 11,246,516 shares of the company’s stock, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 3.30% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Immatics
Hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC raised its holdings in shares of Immatics by 10.7% during the fourth quarter. Perceptive Advisors LLC now owns 10,383,456 shares of the company’s stock valued at $109,026,000 after acquiring an additional 1,000,000 shares during the last quarter. Sofinnova Investments Inc. boosted its stake in shares of Immatics by 54.2% in the fourth quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock worth $36,073,000 after acquiring an additional 1,207,705 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Immatics by 5.5% during the second quarter. Wellington Management Group LLP now owns 1,647,852 shares of the company’s stock worth $16,693,000 after purchasing an additional 85,960 shares in the last quarter. Troluce Capital Advisors LLC purchased a new stake in shares of Immatics during the first quarter worth approximately $2,460,000. Finally, Tidal Investments LLC increased its position in shares of Immatics by 0.7% during the second quarter. Tidal Investments LLC now owns 171,499 shares of the company’s stock worth $1,737,000 after purchasing an additional 1,110 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.
About Immatics
Immatics N.V. (NASDAQ: IMTX) is a biotechnology company focused on developing T cell receptor (TCR)-based therapies for the treatment of cancer. The company identifies cancer targets and designs treatments intended to direct a patient’s immune system toward tumor cells, including solid tumors that may be difficult to address with conventional immunotherapies.
Immatics’ technology platforms support several therapeutic approaches, including TCR-engineered T-cell therapies and TCR-based bispecific molecules that can engage both cancer targets and T cells.
Featured Articles
- Five stocks we like better than Immatics
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
- 3 Stocks Delivering Bigger Dividends Despite Market Uncertainty
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
